Orexo Annual Report 2010

Net turnover, SEKM

2010	210.5
2009	236.1

Loss after tax, SEKM

2010	-89.2
2009	-98.1

Loss per share, SEKM

2010	-3.81
2009	-4.32

Cash and cash equiv, SEKM

2010	135.8
2009	87.4

Read more

Novo A/S becomes a major shareholder

Global R&D alliance with OMJ for new drugs to treat respiratory diseases

Successful phase I trial results for OX219 for the treatment of opioid dependence

• Introduction
  • The Year in Brief
  • CEO’s Message
• Report on operations
  • Board of Directors’ Report
  • Key events during 2010
  • Significant events after the end of the fiscal year
  • Strategy
  • Orexo – a specialty pharma company showing strong growth
  • Proprietary programs
  • Financial assets
    • Abstral
    • Edluar
    • OX-NLA
    • OX17
    • OX-MPI
    • OX-CLI
    • OX-ESI
    • Kibion AB
    • ProStrakan AB
    • Arachidonic acid research
  • Employees and sustainable development
  • The Orexo share
  • Financial trends during 2010
• Financial report
  • Consolidated financial statements of operations
  • Consolidated statement of comprehensive income
  • Consolidated balance sheets
  • Changes in consolidated shareholders’ equity
  • Consolidated cash flow statement
  • Parent Company income statements
  • Parent Company statement of comprehensive income
  • Parent Company balance sheets
  • Changes in Parent Company’s shareholders’ equity
  • Parent Company cash flow statement
  • Notes
    • NOTE 1 GENERAL INFORMATION
    • NOTE 2 SUMMARY OF IMPORTANT ACCOUNTING POLICIES
    • NOTE 3 FINANCIAL RISK MANAGEMENT
    • NOTE 4 ACCOUNTING POLICIES OF THE PARENT COMPANY
    • NOTE 5 CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS
    • NOTE 6 SEGMENT INFORMATION
    • NOTE 7 TANGIBLE FIXED ASSETS
    • NOTE 8 INTANGIBLE FIXED ASSETS
    • NOTE 9 DEPRECIATION/AMORTIZATION
    • NOTE 10 SHARES IN SUBSIDIARIES AND JOINT VENTURES
    • NOTE 11 FINANCIAL INSTRUMENTS BY CATEGORY
    • NOTE 12 INVENTORIES
    • NOTE 13 ACCOUNTS RECEIVABLE AND OTHER RECEIVABLES
    • NOTE 14 CASH AND CASH EQUIVALENTS
    • NOTE 15 SHARE CAPITAL AND OTHER CAPITAL CONTRIBUTIONS
    • NOTE 16 RESERVES
    • NOTE 17 PROVISIONS
    • NOTE 18 BORROWING
    • NOTE 19 ACCOUNTS PAYABLE AND OTHER LIABILITIES
    • NOTE 20 PLEDGED ASSETS
    • NOTE 21 CONTINGENT LIABILITIES
    • NOTE 22 DISTRIBUTION OF REVENUE
    • NOTE 23 COSTS BY TYPE OF COST
    • NOTE 24 AUDITORS' FEES
    • NOTE 25 EXCHANGE-RATE DIFFERENCES
    • NOTE 26 FINANCIAL REVENUES AND EXPENSES
    • NOTE 27 REMUNERATION TO EMPLOYEES
    • NOTE 28 INCOME TAX
    • NOTE 29 DEFERRED INCOME TAX
    • NOTE 30 EARNINGS PER SHARE
    • NOTE 31 SHARE DIVIDENDS
    • NOTE 32 UNDERTAKINGS
    • NOTE 33 DISCLOSURES ON THE CASH FLOW STATEMENT
    • NOTE 34 RELATED PARTY TRANSACTIONS
    • NOTE 35 HOLDINGS IN JOINT VENTURES
    • NOTE 36 ACQUISITION OF OPERATIONS
    • NOTE 37 EVENTS AFTER THE CLOSING DATE
    • NOTE 38 INFORMATION ABOUT OREXO AB (PUBL)
  • Audit report
  • Definitions of key figures
• Corporate governance
  • Corporate Governance Report
  • Auditor’s statement concerning the Corporate Governance Report
  • Internal control
  • Board of directors
  • Management
  • Financial information in brief
• Other information
  • Other information
  • Glossary

© 2009 Orexo AB (publ), Contact: info@orexo.com, +46 (0)18 780 88 00, Box 303, SE-751 05 Uppsala, Sweden, VAT No. SE556500-060001, Legal notice, About cookies